Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-09-07
2003-03-25
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S04400A, C514S045000, C514S262100, C514S263100, C514S263200, C514S263230, C514S256000, C514S257000, C514S258100, C544S262000, C544S264000
Reexamination Certificate
active
06537974
ABSTRACT:
BACKGROUND
1. Field of the Invention
This invention relates to a method of treating atrial arrhythmias that minimizes undesirable side effects, comprising administration of an adenosine A
1
receptor agonist in low doses.
2. Background Information
Atrial arrhythmias, such as primary atrial fibrillation, atrial flutter, and paroxysmal atrial tachycardia (PSVT), are abnormal heart rhythms that are due to a variety of factors. Arrhythmias can range from incidental, asymptomatic clinical findings to life-threatening abnormalities. Arrhythmias account for a significant percentage of the causes of death in human. Thus, it is desirable to develop methods of mitigating the effects of arrhythmia.
A variety of anti-arrhythmic drug therapies are presently available. These compounds, however, have significant limitations. Digoxin, for example, has a delayed onset of action (about 30 min) and its peak effects are not observed for 3 to 4 hours after administration. Other examples are &bgr;-blockers and calcium-channel blockers, which widely used to treat arrhythmias, can cause hypotension and have negative inotropic effects.
Adenosine is a naturally occurring compound that is highly effective in ameliorating arrhythmia. However, adenosine has a wide variety of physiological effects. The multiple activities of adenosine are mediated by its interactions with a family of adenosine receptors, known as the adenosine A
1
, A
2A
, A
2B
, and A
3
receptors, each of which regulates distinct biological activites. For example, adenosine binds to adenosine A
1
receptors in heart resulting in a dromotrophic effect while the binding of adenosine to A
2A
results in coronary vasodilation. Likewise adenosine binds to adenosine A
2B
receptors thus affecting a wide array of activities including angiogenesis, cellular proliferation, and apopotosis, to name a few. On the other hand, adenosine binds toA
3
receptors on mast cells thereby stimulating degranulation and the release of histamine.
The anti-arrhythmic effects of adenosine are due exclusively to its interaction with the adenosine A
1
receptor subtype. However, contemporaneous binding of adenosine to the subtypes, A
2A
, A
2B
, and A
3
results in undesirable side effects, such as vasodilation, changes in the heart rate and mast cell degradation. Thus, the lack of selectivity of adenosine for the A
1
receptor subtype makes adenosine unsuitable for the treatment of arrhythmias. Additionally, adenosine has a short half-life (~10 sec) making it ineffective in any condition that requires prolonged drug action.
Thus, there is a need for a method of treating arrhythmias with therapeutic agents that are selective for the adenosine A
1
receptor, have sufficiently long half-lives, and have few side effects. Preferred compounds would be active at very low doses, since lower doses provide less opportunity for side effects.
New classes of agonists that bind to adenosine A
1
receptors and that are useful in treating arrhythmias are disclosed in U.S. Pat. No. 5,789,416, the entire disclosure of which is hereby incorporated by reference. These compounds have a high specificity for the adenosine A
1
receptor subtypes, but like all therapeutic compounds, can potentially cause side effects.
The effective dose of the compounds of '416 is disclosed to be in the range of 0.01-100 mg/kg. Surprisingly, we have discovered that the compounds are active at much lower doses (0.0003-0.009 mg/kg) than those disclosed as effective in '416. Accordingly, a novel and effective method of treating arrhythmias is provided that restores sinus rhythm without slowing the sinus rate and is virtually free of undesirable side effects, such as changes in mean arterial pressure, blood pressure, heart rate, or other adverse effects.
SUMMARY OF THE INVENTION
It is an object of this invention to provide an effective method of treating atrial arrhythmias in a mammal while minimizing undesirable side effects. Accordingly, in a first aspect, the invention relates to a method of treating atrial arrhythmias in a mammal comprising administration of a therapeutically minimal dose of an adenosine A
1
receptor agonist of Formula I to a mammal in need thereof:
Wherein:
R
1
is an optionally substituted heterocyclic group, preferably monocyclic; and said minimal dose is in the range of 0.0003-0.009 mg/kg.
In a more preferred embodiment, R
1
is 3-tetrahydrofuranyl, 3-tetrahydrothiofuranyl, 4-pyranyl and 4-thiopyranyl.
The compounds of Formula I exist as a racemic mixture, or as individual isomers. Most preferred is 6-(3-(R)-aminotetrahydrofuranyl) purine riboside.
The most preferred embodiment of the invention is a method of treating atrial arrhythmias in a mammal comprising administering a therapeutically minimal dose of 0.0003-0.009 mg/kg of 6-(3-(R)-N-aminotetrahydrofuranyl) purine riboside, hereafter referred to as CVT-510.
REFERENCES:
patent: 4364922 (1982-12-01), Berne et al.
patent: 4713455 (1987-12-01), Furrer et al.
patent: 4954504 (1990-09-01), Chen et al.
patent: 4980379 (1990-12-01), Belardinelli et al.
patent: 5446046 (1995-08-01), Belardinelli et al.
patent: 5631260 (1997-05-01), Belardinelli et al.
patent: 5736528 (1998-04-01), Belardinelli et al.
patent: 5789416 (1998-08-01), Lum et al.
patent: 0 062 921 (1982-10-01), None
patent: WO 97/24363 (1997-07-01), None
patent: WO 98/08855 (1998-03-01), None
CV Therapeutics Inc.
McDonnell & Boehnen Hulbert & Berghoff
McIntosh Traviss
Wilson James O.
LandOfFree
Method of treating arrhythmias does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating arrhythmias, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating arrhythmias will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3072432